Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Nova Eye Medical reports surge in USA sales despite Medicare reimbursement uncertainty

  • In News
  • January 9, 2024
  • Alinda Gupta
Nova Eye Medical reports surge in USA sales despite Medicare reimbursement uncertainty

Aussie MedTech company Nova Eye Medical (ASX: EYE) has kicked off the new year with good news for investors, recording an impressive $7.6 million in sales in the US for its glaucoma surgical devices during the six months concluding on December 31, 2023 (unaudited). 

This represents a remarkable 65% growth compared to the previous corresponding period (PCP).

What’s more, this follows the many challenges Nova Eye faced in the final months of 2023 as USA sales revenue in November and December took a hit due to uncertainties surrounding Medicare reimbursement for Nova Eye Medical’s iTrack™ portfolio. 

The cloud of doubt stemmed from local coverage determinations (LCDs) proposed by five Medicare Administrative Contractors (MACs). The situation led to a temporary setback, with the US saying that Medicare, its national Healthcare policy, will no longer cover glaucoma surgeries. This was later withdrawn, bringing relief and affirmed continued reimbursement coverage for the iTrack™ portfolio.

The Company also faced a potential setback with the LCDs proposing restrictions or denials of coverage for several procedures, including canaloplasty. Despite this hurdle, Nova Eye Medical Limited managed to achieve significant market penetration in the USA since May 2023.

Nova Eye Medical Limited is a medical technology company specialising in the development, manufacturing, and sale of proprietary ophthalmic treatment technologies and devices. Among its globally used technologies is iTrack’s minimally invasive glaucoma surgery (MIGS), a surgical device designed to restore the eye’s natural outflow pathway. This solution aims to lower intraocular pressure and reduce patient reliance on anti-glaucoma medications for mild to moderate glaucoma, thus transforming into a potential cure for some forms of blindness.

The pivotal factor driving Nova Eye Medical’s robust performance during the H1 FY24 period was the widespread adoption of its new iTrack™ Advance. Launched in the USA in May 2023, the iTrack™ Advance received positive acclaim from both new and existing ophthalmologist customers. The steady rise in demand for this innovative surgical device contributed significantly to the overall sales growth.

Looking forward, the withdrawal of the proposed reimbursement changes by the MACs is expected to pave the way for accelerated sales growth in the second half of FY24. The Company anticipates releasing unaudited global sales results for the period ending December 31, 2023, during the week commencing February 5, 2024.

In the first four months of FY24, Nova Eye Medical witnessed a remarkable global sales growth (excluding China) of 39%, surpassing the $5.9 million mark. Despite initial challenges, the Company has managed to cushion the blow.

Besides achieving its American dream, Nova Eye has secured several important registrations in key strategic markets outside of the USA during the period. For instance, registrations for iTrack Advance in China and South Korea are underway.

It is also seeking commercialisation opportunities for 2RT, its drug addressing AMD, an intermediate stage disease causing blindness in over 50 million people globally.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  •  
  •  
  •  
  •  
  • asx eye
  • itrack
  • Medicare Administrative Contractors
  • medtech
  • MIGs
  • nova eye medical
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alinda Gupta
Alinda is a Business Reporter for The Sentiment
Latest posts by Alinda Gupta (see all)
  • Ovanti’s iSentric signs contracts worth $14.4m with Malaysian commercial bank - June 27, 2024
  • Baby Bunting fights back from retail downturn with 5-year strategy, includes Gen-Z focus and self-funded growth - June 27, 2024
  • CLEO meets with US FDA to develop strategy for ovarian cancer test launch - June 26, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.